Astec Lifesciences
Astec Lifesciences Ltd valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Astec Lifesciences Ltd, framed against the sector median so the premium or discount is obvious at a glance.
Valuation
Profitability
Growth
Financial Health
Astec Lifesciences Ltd financials: P&L, balance sheet, cash flow, ratios.
Twelve years of audited numbers for Astec Lifesciences Ltd, switchable between annual and quarterly views, consolidated or standalone.
Astec Lifesciences Ltd reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹1,763.64 Cr and reported EPS of ₹-37.79.
| Period | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 371 | 431 | 523 | 555 | 677 | 628 | 458 | 381 | 448 |
| Other Income | 8 | 11 | 12 | 8 | 10 | 13 | 6 | 6 | 5 |
| Total Income | 379 | 442 | 535 | 563 | 687 | 641 | 464 | 387 | 453 |
| Cost of Goods Sold (COGS) | 235 | 279 | 339 | 342 | 387 | 401 | 319 | 297 | 298 |
| Gross Profit | 136 | 151 | 184 | 213 | 290 | 227 | 139 | 84 | 150 |
| +Operating Expenses | 67 | 75 | 99 | 101 | 136 | 151 | 145 | 151 | 154 |
| EBITDA | 69 | 76 | 85 | 112 | 154 | 76 | -6 | -66 | -5 |
| +Non-Operating Expenses | 29 | 32 | 36 | 30 | 43 | 54 | 61 | 80 | 77 |
| Profit Before Tax (PBT) | 56 | 56 | 61 | 89 | 121 | 35 | -62 | -141 | -81 |
| +Tax Expense | 21 | 20 | 14 | 24 | 31 | 9 | -15 | -6 | -0 |
| Profit After Tax (PAT) | 35 | 36 | 48 | 65 | 90 | 26 | -47 | -135 | -81 |
| Earnings Per Share (EPS) | 15.64 | 15.99 | 21.24 | 29.07 | 40.12 | 11.41 | -20.94 | -60.12 | -36.31 |
| Diluted Shares Outstanding (Nos.) | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| +Additional Disclosures | 562 | 666 | 812 | 816 | 953 | 1,007 | 844 | 825 | 831 |
| Sales Growth % | — | 16.19 | 21.28 | 6.17 | 21.93 | -7.15 | -27.06 | -16.78 | 17.53 |
| YoY Sales Growth % | — | 16.19 | 21.28 | 6.17 | 21.93 | -7.15 | -27.06 | -16.78 | 17.53 |
| Material Cost % | 60 | 68 | 64 | 62 | 66 | 73 | 70 | 65 | 60 |
| Employee Cost % | 6 | 6 | 6 | 7 | 7 | 8 | 13 | 16 | 14 |
| Other Cost % | 12 | 12 | 13 | 11 | 13 | 16 | 18 | 23 | 20 |
| OPM % | 19 | 18 | 16 | 20 | 23 | 12 | -1 | -17 | -1 |
| Tax % | 37 | 36 | 23 | 27 | 26 | 27 | 24 | 4 | 0 |
| Profit Growth % | — | 2.08 | 32.89 | 36.91 | 38.13 | -71.53 | -283.21 | -187.29 | 39.96 |
| Gross Margin % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA Margin % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.00 | -0.00 | -0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.00 | -0.00 | -0.00 |
| Additional Fields | 54 | 57 | 62 | 86 | 120 | 43 | -42 | -110 | -49 |
Astec Lifesciences segment analysis: revenue and profit mix.
Disclosed business segments at Astec Lifesciences with their share of revenue and profit, switchable between consolidated and standalone reporting.
Astec Lifesciences discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
Astec Lifesciences Ltd investment thesis: bull case, bear case, and the flip lines.
Why someone would buy Astec Lifesciences Ltd, why someone wouldn't, and the quantitative tripwires that would force the call to flip.
Astec Lifesciences Ltd's investment case rests on 6 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Robust 72.42% promoter holding signals strong insider confidence and stability.
Diversified product portfolio includes fungicides, herbicides, insecticides, and specialty chemicals.
Strong international presence, exporting products to 17 countries globally.
Benefits from being a subsidiary of Godrej Agrovet, leveraging resources.
Consistent demand in Pesticides & Agrochemicals industry offers inherent stability.
What can break it.
Reported substantial quarterly net loss of -24.4 Cr, indicating operational challenges.
Negative ROE -45.3% and ROCE -12.9% highlight severe profitability issues.
High debt-to-equity ratio of 2.36 elevates financial risk significantly.
Quarterly sales declined -25.20%, reflecting contraction in revenue generation.
Stock price 672.00 is near its 52-week low of 630.00.
What would change my mind.
Reassess if quarterly profit growth prints below 0% for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 115.34. Balance sheet risk re-prices growth multiples fast.
Astec Lifesciences Ltd peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Astec Lifesciences Ltd is highlighted for quick read-across.
Quick Compare
Peer Comparison
Astec Lifesciences Ltd technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Astec Lifesciences Ltd — derived from the live tape, not yesterday's close.
Astec Lifesciences Ltd last traded at ₹789.45 with an intraday range of ₹784.2–₹808 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹789.45| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 851.17 | +61.72 | +7.82% |
| R3 | 827.37 | +37.92 | +4.80% |
| R2 | 817.68 | +28.23 | +3.58% |
| R1 | 803.57 | +14.12 | +1.79% |
| PIVOT | 793.88 | 4.43 | 0.56% |
| CURRENT | 789.45 | — | — |
| S1 | 732.17 | -57.28 | -7.26% |
| S2 | 755.97 | -33.48 | -4.24% |
| S3 | 770.08 | -19.37 | -2.45% |
| S4 | 779.77 | -9.68 | -1.23% |
ASTEC is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: 784.2 ~ 796.35
Trading Inside opening range
Astec Lifesciences Ltd chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Astec Lifesciences Ltd — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
Astec Lifesciences Ltd delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Astec Lifesciences Ltd over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Astec Lifesciences Ltd stood at 54.3% of traded volume, against a 20-day average of 32.0%.
Astec Lifesciences announcements: results, concalls, ratings, M&A.
Filings Astec Lifesciences sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Astec Lifesciences files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 87 documents below.
Copy of Newspaper Publication
Astec LifeSciences Limited has informed the Exchange about Copy of Newspaper Publication
Spurt in Volume
Significant increase in volume has been observed in Astec LifeSciences Limited. The Exchange, in order to ensure that investors have latest relevant…
Copy of Newspaper Publication
Astec LifeSciences Limited has informed the Exchange about Copy of Newspaper Publication
General Updates
Astec LifeSciences Limited has informed the Exchange about Grant of Stock Options.
Copy of Newspaper Publication
Astec LifeSciences Limited has informed the Exchange about Copy of Newspaper Publication
Investor decks & rating reports.
Astec Lifesciences insider trading: promoter and management activity.
Promoter, director and designated-employee transactions in Astec Lifesciences as reported to SEBI — buying and selling signals from the people who know the business best.
Astec Lifesciences insider activity below tracks 4 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| Tanya Dubash | Insider | 01 Jan 2025 | buy | +1.35 L | ₹14.78 Cr | ₹1,094.96 |
| Pirojsha Godrej | Insider | 01 Jan 2025 | buy | +1.35 L | ₹14.77 Cr | ₹1,094.96 |
| Nisaba Godrej | Insider | 01 Jan 2025 | buy | +1.35 L | ₹14.78 Cr | ₹1,094.96 |
| Nadir Godrej | Insider | 01 Jan 2025 | buy | +4.05 L | ₹44.32 Cr | ₹1,094.96 |
Astec Lifesciences dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Astec Lifesciences has declared, sequenced by announce and record date.
Astec Lifesciences corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Astec Lifesciences Ltd: business, sector, key facts.
What Astec Lifesciences Ltd does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Astec Lifesciences Ltd operates in the Basic Materials, listed as NSE: ASTEC, BSE: 533138.
Astec LifeSciences Limited is a prominent Indian company specializing in the manufacturing and distribution of agrochemical active ingredients and pharmaceutical intermediates. Its primary focus lies within the agrochemical sector, providing a diverse range of products designed to enhance agricultural yields and protect crops from various diseases and pests. A significant portion of their business involves the production and sale of triazole fungicides, utilized extensively in treating field crops against a variety of fungal infections.
The company's fungicide offerings are tailored to address specific crop needs. They provide foliar treatments to combat diseases such as scab, powdery mildew, shot-hole, blossom blight, and rust. Furthermore, Astec LifeSciences supplies seed treatments for crops like cotton, maize, barley, rice, and wheat, safeguarding seeds and soil from various pathogens. Their product range even extends to post-harvest treatments, ensuring crop preservation throughout the entire agricultural cycle. Beyond fungicides, they also produce and market a selection of herbicides and insecticides, catering to a broader spectrum of crop protection needs.
Beyond the core agricultural market, Astec LifeSciences also produces specialty chemicals. This diversification allows the company to tap into different industries, further enhancing its revenue streams. The incorporation of a food additive and wood preservative product line suggests a strategic expansion aimed at leveraging their chemical expertise into related sectors. This diversification strategy mitigates reliance on any single product category and contributes to the company's overall financial stability.
A key aspect of Astec LifeSciences' business strategy is its commitment to export markets. The company actively engages in international trade, supplying its products to global customers. This international presence positions Astec LifeSciences as a key player in the broader agrochemical market, enhancing its visibility and generating additional revenue streams. Established in 1994 and headquartered in Mumbai, India, Astec LifeSciences Limited operates as a subsidiary of Godrej Agrovet Limited, benefiting from the larger parent company's resources and market expertise.
Questions investors ask about Astec Lifesciences Ltd (ASTEC).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Astec Lifesciences Ltd (ASTEC)?
The current share price of Astec Lifesciences Ltd (ASTEC) is ₹789.45. Today, the stock has declined by ₹0.45 (0.06%), trading in a range of ₹784.2 to ₹808. The stock opened at ₹794.95 with a trading volume of 63,546 shares.
02Is Astec Lifesciences Ltd stock a good investment for long-term?
Astec Lifesciences Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹1,763.64 crores, P/E ratio of 0.00, ROE of -25.84%, and ROCE of -12.90%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Astec Lifesciences Ltd stock?
The 52-week high price of Astec Lifesciences Ltd (ASTEC) is ₹998.4, while the 52-week low is ₹513.4. Currently trading at ₹789.45, the stock is 56.9% away from its 52-week low and 20.9% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Astec Lifesciences Ltd stock at the current price?
Whether to buy Astec Lifesciences Ltd stock at ₹789.45 depends on multiple factors. The stock is currently trading with a P/E ratio of 0.00 and P/B ratio of 4.39. Today's performance shows a loss of 0.06%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Astec Lifesciences Ltd and when is the next dividend?
Astec Lifesciences Ltd offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹789.45, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Astec Lifesciences Ltd?
Astec Lifesciences Ltd's key financial metrics include: P/E Ratio: 0.00, P/B Ratio: 4.39, ROE: -25.84%, ROCE: -12.90%, Dividend Yield: 0.00%, EPS: ₹-37.79, Book Value: ₹175.23, and Debt-to-Equity: 114.84. The company's market cap stands at ₹1,763.64 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Astec Lifesciences Ltd stock performing today in the market?
Astec Lifesciences Ltd stock opened at ₹794.95 and is currently trading at ₹789.45, showing a decline of ₹0.45 (0.06%). The intraday high is ₹808 and low is ₹784.2. The trading volume stands at 63,546 shares, indicating moderate market participation today.
08What is the P/E ratio of Astec Lifesciences Ltd and what does it indicate?
Astec Lifesciences Ltd has a Price-to-Earnings (P/E) ratio of 0.00, which means investors are willing to pay ₹0.00 for every ₹1 of earnings. With an EPS of ₹-37.79, this P/E ratio suggests the stock may be undervalued or facing growth challenges. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Astec Lifesciences Ltd (ASTEC) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Bhagiradha Chemicals & Industries (BHAGCHEM) Share PricePeer
- Bharat Rasayan (BHARATRAS) Share PricePeer
- Dhanuka Agritech (DHANUKA) Share PricePeer
- Dharmaj Crop Guard (DHARMAJ) Share PricePeer
- Heranba Industries (HERANBA) Share PricePeer
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy